The global CRISPR market is forecasted to grow from $3.48 billion in 2026 to $6.12 billion by 2031, at a CAGR of 12%. Growth is fueled by expanding use in drug discovery, gene therapy, precision medicine, and agriculture, alongside technological advances like base and prime editing. The US market is expected to lead growth due to strong research infrastructure and investment. Key players include Thermo Fisher Scientific, Merck, and Agilent Technologies, with rising demand for CRISPR kits and enzymes supporting market expansion.
As of Oct 27, 2026 22:22 WIB, Merck & Co., Inc. (MRK), a key player in the CRISPR market, trades at USD 142.41 with a 1-day gain of 1.28% on Pluang. Agilent Technologies (A), another major company in the sector, is priced at USD 177.65, up 0.96% for the day. The strong buying interest on Pluang, with 99% buy orders for MRK, highlights investor confidence in these stocks amid the expanding gene editing market.
Moderna's stock fell about 7.4% following the release of Phase 3 trial data for its experimental cancer vaccine, intismeran, developed with Merck. The results tempered investor enthusiasm, reflecting that expectations had been very high. Merck's shar...
Moderna's stock fell 7% after its personalized melanoma vaccine, despite meeting its primary goal in a late-stage trial, showed less impact on distant cancer spread than earlier studies suggested. This has led investors to reassess the commercial pot...
Merck will report its Q3 2026 results on October 29, with investors focused on whether new drug launches like LIPFENDRA, QLEX, and WINREVAIR can compensate for the expected loss of patent exclusivity for Keytruda in 2028. Last quarter, revenue grew 5...
Moderna and Merck released Phase 3 trial results showing their personalized mRNA cancer vaccine, combined with Keytruda, reduces melanoma recurrence or death risk by 42% compared to Keytruda alone. Specialists see this as a significant breakthrough t...
Moderna's stock dropped 4% following an earlier 18% plunge after the release of positive late-stage results for its personalized melanoma vaccine co-developed with Merck. Although the vaccine showed a reduction in melanoma recurrence risk, the result...
